USSN: 10/737,144 Atty Dkt: DURE-050

## COMPLETE LISTING OF THE CLAIMS

1. (Currently Amended) An oral dosage form comprising:

a formulation that, upon exposure to an aqueous environment, forms a network within the formulation and an outer surface, wherein the formulation comprises:

a drug;

<u>about 30 – 90 weight percent of sucrose acetate isobutyrate (SAIB) as</u> a high viscosity liquid carrier material (HVLCM);

a network former;

a rheology modifier <u>selected from the group consisting of isopropyl myristate</u> (IPM), ethyl oleate, triethyl citrate, dimethyl phthalate, benzyl benzoate, and a <u>caprylic/capric triglyceride</u>; and

a solvent, wherein said formulation provides for release of the drug over a prolonged period of time of at least an hour and is resistant to drug extraction using ethanol.

- 2 79. (Canceled)
- 80. (New) The dosage form of claim 1, wherein the formulation comprises from 1 8.6 weight percent of the network former.
- 81. (New) The dosage form of claim 80, wherein the network former comprises cellulose acetate butyrate (CAB).
- 82. (New) The dosage form of claim 1, wherein the drug is selected from the group consisting of opioids, CNS depressants, and stimulants.
- 83. (New) The dosage form of claim 1, wherein the formulation comprises from 20 50 weight percent of the solvent.

USSN: 10/737,144 Atty Dkt: DURE-050 PATENT

84. (New) The dosage form of claim 83, wherein the solvent is selected from the group consisting of ethyl lactate (EL), triacetin, dimethyl sulfoxide (DMSO), propylene carbonate, N-methylpyrrolidone (NMP), ethyl alcohol, benzyl alcohol, glycofurol, alphatocoperol, isopropyl alcohol, diethyl phthalate, polyethylene glycol 400 (PEG 400), triethyl citrate, benzyl benzoate, and a caprylic/capric triglyceride.